LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
Sergio Regufe da MotaSarah BaileyRosemary A StrivensAnnette L HaydenLeon R DouglasPatrick J DuriezM Teresa BorrelloHanae BenelkebirA GanesanGraham PackhamSimon J CrabbPublished in: Cancer cell international (2018)
LSD1 contributes to activation of both the wild type and V7 splice variant forms of the androgen receptor and can be therapeutically targeted in models of CRPC. Further development of this approach is warranted.
Keyphrases